 Cui J, Eitzman DT, Westrick RJ, et al.
Spontaneous thrombosis in mice carrying the
factor V Leiden mutation. Blood. 2000;96(13):
4222-4226.
25. Eitzman DT, Westrick RJ, Shen Y, et al.
Homozygosity for factor V Leiden leads to
enhanced thrombosis and atherosclerosis in
mice. Circulation. 2005;111(14):1822-1825.
26. Kerlin BA, Yan SB, Isermann BH, et al. Survival
advantage associated with heterozygous factor V
Leiden mutation in patients with severe sepsis
and in mouse endotoxemia. Blood. 2003;102(9):
3085-3092.
27. Wang H, Madhusudhan T, He T, et al. Low but
sustained coagulation activation ameliorates
glucose-induced podocyte apoptosis: protective
effect of factor V Leiden in diabetic nephropathy.
Blood. 2011;117(19):5231-5242.
28. Burstyn-Cohen T, Heeb MJ, Lemke G. Lack
of protein S in mice causes embryonic lethal
coagulopathy and vascular dysgenesis. J Clin
Invest. 2009;119(10):2942-2953.
29. Okuda T, Higashi Y, Kokame K, Tanaka C,
Kondoh H, Miyata T. Ndrg1-deficient mice exhibit
a progressive demyelinating disorder of peripheral
nerves. Mol Cell Biol. 2004;24(9):3949-3956.
30. Banno F, Kokame K, Okuda T, et al. Complete
deficiency in ADAMTS13 is prothrombotic, but
it alone is not sufficient to cause thrombotic
thrombocytopenic purpura. Blood. 2006;107(8):
3161-3166.
31. Yamamoto H, Kokame K, Okuda T, Nakajo Y,
Yanamoto H, Miyata T. NDRG4 protein-deficient
mice exhibit spatial learning deficits and
vulnerabilities to cerebral ischemia. J Biol Chem.
2011;286(29):26158-26165.
32. Eura Y, Yanamoto H, Arai Y, Okuda T, Miyata T,
Kokame K. Derlin-1 deficiency is embryonic lethal,
Derlin-3 deficiency appears normal, and Herp
deficiency is intolerant to glucose load and
ischemia in mice. PLoS One. 2012;7(3):e34298.
33. Fern´ andez JA, Heeb MJ, Xu X, Singh I, Zlokovic
BV, Griffin JH. Species-specific anticoagulant
and mitogenic activities of murine protein S.
Haematologica. 2009;94(12):1721-1731.
34. Diaz JA, Alvarado CM, Wrobleski SK, et al. The
electrolytic inferior vena cava model (EIM) to
study thrombogenesis and thrombus resolution
with continuous blood flow in the mouse. Thromb
Haemost. 2013;109(6):1158-1169.35. Tashima Y, Banno F, Akiyama M, Miyata T.
Influence of ADAMTS13 deficiency on venous
thrombosis in mice. Thromb Haemost. 2015;
114(1):206-207.
36. Smith SA, Choi SH, Davis-Harrison R, et al.
Polyphosphate exerts differential effects on blood
clotting, depending on polymer size. Blood. 2010;
116(20):4353-4359.
37. M¨ uller F, Mutch NJ, Schenk WA, et al. Platelet
polyphosphates are proinflammatory and
procoagulant mediators in vivo. Cell. 2009;139(6):
1143-1156.
38. Yanamoto H, Nagata I, Niitsu Y, Xue JH, Zhang Z,
Kikuchi H. Evaluation of MCAO stroke models
in normotensive rats: standardized neocortical
infarction by the 3VO technique. Exp Neurol.
2003;182(2):261-274.
39. Yang D, Nakajo Y, Iihara K, et al. An integrated
stroke model with a consistent penumbra for the
assessment of neuroprotective interventions.
Eur Neurol. 2014;71(1-2):4-18.
40. Wojcik BM, Wrobleski SK, Hawley AE, Wakefield
TW, Myers DD Jr, Diaz JA. Interleukin-6:
a potential target for post-thrombotic syndrome.
Ann Vasc Surg. 2011;25(2):229-239.
41. DeRoo EP, Wrobleski SK, Shea EM, et al. The
role of galectin-3 and galectin-3-binding protein
in venous thrombosis. Blood. 2015;125(11):
1813-1821.
42. Kita T, Banno F, Yanamoto H, Nakajo Y, Iihara K,
Miyata T. Large infarct and high mortality by
cerebral ischemia in mice carrying the factor V
Leiden mutation. J Thromb Haemost. 2012;10(7):
1453-1455.
43. MacArthur DG, Manolio TA, Dimmock DP, et al.
Guidelines for investigating causality of sequence
variants in human disease. Nature. 2014;
508(7497):469-476.
44. Rodr ´ıguez de C´ ordoba S, P´ erez-Blas M, Ramos-
Ruiz R, S´ anchez-Corral P, Pardo-Manuel de
Villena F, Rey-Campos J. The gene coding for the
beta-chain of C4b-binding protein (C4BPB) has
become a pseudogene in the mouse. Genomics.
1994;21(3):501-509.
45. Maruyama K, Akiyama M, Kokame K, Sekiya A,
Morishita E, Miyata T. ELISA-based detection
system for protein S K196E mutation, a genetic
risk factor for venous thromboembolism. PLoS
One. 2015;10(7):e0133196.
46. Liu S, Zhen G, Meloni BP, Campbell K, Winn HR.
Rodent stroke model guidelines for preclinical
stroke trials (1st edition). J Exp Stroke Transl
Med . 2009;2(2):2-27.
47. Zhu D, Wang Y, Singh I, et al. Protein S controls
hypoxic/ischemic blood-brain barrier disruption
through the TAM receptor Tyro3 and sphingosine
1-phosphate receptor. Blood. 2010;115(23):
4963-4972.
48. Zhong Z, Wang Y, Guo H, et al. Protein S protects
neurons from excitotoxic injury by activating the
TAM receptor Tyro3-phosphatidylinositol 3-
kinase-Akt pathway through its sex hormone-
binding globulin-like region. J Neurosci. 2010;
30(46):15521-15534.
49. Griffin JH, Zlokovic BV, Mosnier LO. Activated
protein C: biased for translation. Blood.